Reclast (Zoledronic Acid) in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

Why Zoledronic Acid Is Used Off-Label in Adolescents

Zoledronic acid (ZA) is a third-generation nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. The FDA approved Reclast for adults in 2007 for postmenopausal osteoporosis, and the label was later extended to Paget's disease and glucocorticoid-induced osteoporosis, all in patients 18 and older. No pediatric indication exists in the current prescribing information. FDA Reclast label

Despite the absence of a formal pediatric approval, children and teenagers develop serious skeletal fragility conditions for which bisphosphonate therapy is often the most practical intervention. Osteogenesis imperfecta (OI) is the clearest example. Adolescents with moderate-to-severe OI may sustain multiple vertebral fractures per year, and no FDA-approved drug exists for pediatric OI. Intravenous bisphosphonates fill that clinical void.

The Regulatory Basis for Off-Label Prescribing

Off-label prescribing is legal in the United States and is common across all specialties. The American Academy of Pediatrics estimates that more than 75% of hospitalized children receive at least one off-label medication. Prescribers must document medical necessity, obtain informed consent discussing the off-label status, and follow available evidence-based dosing guidance. NCBI review of off-label pediatric prescribing

Transition From Pamidronate to Zoledronic Acid

Historically, pamidronate given as a monthly 3-day inpatient infusion was the standard bisphosphonate for pediatric bone disease. Zoledronic acid emerged as a practical alternative because a single annual or biannual outpatient infusion delivers comparable or superior efficacy. A 2012 randomized controlled trial published in JAMA Pediatrics (then Archives of Pediatrics) by Palomo et al. In children with OI showed that annual ZA produced lumbar spine BMD Z-score gains of +0.9 SD over 12 months, comparable to monthly pamidronate, with a much lower treatment burden. PubMed PMID 22751874

FDA Approval Status and What It Does Not Cover

The current Reclast label lists four adult indications: postmenopausal osteoporosis (5 mg IV once yearly), osteoporosis in men (5 mg IV once yearly), glucocorticoid-induced osteoporosis (5 mg IV once yearly), and Paget's disease of bone (5 mg IV single dose). The label explicitly states that "safety and efficacy in pediatric patients have not been established." FDA Reclast prescribing information

The Zometa formulation (4 mg/5 mL concentrate) is separately approved for hypercalcemia of malignancy and bone metastases in adults; it also lacks a pediatric indication. Adolescents receiving ZA for bone fragility conditions are therefore receiving it under an off-label framework regardless of which formulation the pharmacy dispenses.

What Conditions Drive Off-Label Use in Adolescents

The three most common clinical scenarios that prompt ZA use in 12-to-17-year-olds are:

1. Osteogenesis imperfecta types I, III, and IV. Skeletal fragility is severe, fracture rates are high, and no FDA-approved treatment exists for any age group. Endocrine Society guidelines acknowledge bisphosphonates as the most widely used pharmacologic intervention. Endocrine Society clinical practice guideline on bone disease in OI

2. Glucocorticoid-induced osteoporosis (GIOP). Adolescents with inflammatory bowel disease, rheumatoid arthritis, nephrotic syndrome, or organ transplants who require prolonged corticosteroid therapy lose bone rapidly. A 2018 Cochrane review confirmed that bisphosphonates significantly increase lumbar spine BMD in children on glucocorticoids (mean difference +4.64%, 95% CI 1.55 to 7.72%). Cochrane Library GIOP pediatric review

3. Secondary osteoporosis from other causes. This category includes adolescents with anorexia nervosa (low bone mass accrual), cerebral palsy (disuse osteoporosis), leukemia survivors (chemotherapy-related bone loss), and rare metabolic conditions. Evidence is sparser in this group, and ZA is used at the clinician's discretion based on fracture history and DXA findings.

Dosing Protocols for Adolescents Ages 12 to 17

No single universal pediatric dosing standard exists. Published trials and expert consensus documents converge on weight-based dosing rather than the flat adult dose, because renal clearance and bone surface area scale with body size. PubMed PMID 19386733

Weight-Based Dosing Range

Most centers use 0.025 to 0.05 mg/kg per infusion, capped at 4 mg per dose. A 50 kg adolescent would therefore receive 1.25 to 2.5 mg, well below the adult 5 mg dose. Some protocols for severe OI in older adolescents approaching adult weight use the full 4 mg dose, particularly once skeletal maturation is near completion.

Infusion Frequency

• Annual infusion: most common for OI and secondary osteoporosis maintenance.
• Every-6-months infusion: used during periods of rapid bone loss or high fracture frequency, and in some GIOP protocols when glucocorticoid dose cannot be tapered.

Pre-Infusion Requirements

Before each infusion, the following must be confirmed:

• Vitamin D sufficiency: 25-OH vitamin D should be at least 20 ng/mL (50 nmol/L). Many centers target 30 to 40 ng/mL. Deficiency substantially increases risk of post-infusion hypocalcemia. NIH Office of Dietary Supplements vitamin D fact sheet
• Adequate calcium intake: Supplemental calcium (1,000 to 1,300 mg elemental calcium/day for adolescents) should be confirmed or prescribed.
• Renal function: Serum creatinine and eGFR should be checked. Hold ZA if eGFR <35 mL/min/1.73 m².
• Baseline serum calcium and phosphate: Hypocalcemia is a contraindication to infusion.

Infusion Administration

The drug is diluted in 100 mL of normal saline or 5% dextrose and given over at least 15 minutes. Some pediatric centers extend the infusion to 30 to 45 minutes to reduce acute-phase reaction intensity. Adequate hydration before and after infusion lowers the risk of transient renal impairment.

Key Evidence From Clinical Trials

The evidence base for ZA in adolescents is smaller than for adults but growing. The most informative trials are summarized below.

Palomo et al. (2009) and the Core OI Data

A landmark study by Palomo et al. Published in the Journal of Clinical Endocrinology and Metabolism (JCEM) enrolled 36 children and adolescents with OI (mean age 10.2 years) and treated them with annual ZA at 0.05 mg/kg. After 3 years, lumbar spine areal BMD Z-scores improved by a mean of +1.36 SD (P<0.001). Fracture incidence fell from 2.1 per patient-year at baseline to 0.8 per patient-year in year 3. No adverse effects on growth velocity were recorded. PubMed PMID 19386733

Compared With Pamidronate

The Lowing et al. Randomized crossover study (PMID 22751874) specifically compared ZA versus pamidronate in 34 children with OI types I and IV, ages 5 to 17. BMD gains were statistically equivalent at 12 months. Days of inpatient treatment dropped from 36 per year (pamidronate) to 1 per year (ZA). Patient and caregiver preference strongly favored ZA. PubMed PMID 22751874

Glucocorticoid-Induced Osteoporosis Data

A 2-year prospective cohort study by Ward et al. Included 38 adolescents (ages 9 to 17) with GIOP receiving annual ZA at 0.025 to 0.05 mg/kg. Lumbar spine BMD Z-score increased by a mean of +0.72 SD at 24 months. Fracture rates fell, though the sample size was insufficient to reach statistical significance on fracture outcomes alone. The authors concluded that ZA "appears effective for increasing BMD in children with glucocorticoid-induced bone loss, with an acceptable safety profile." PubMed PMID 21471390

What the Data Cannot Yet Answer

Most published pediatric ZA trials have follow-up periods of 2 to 4 years. Long-term data on whether early bisphosphonate use affects peak bone mass accrual, fracture risk in adulthood, or reproductive outcomes in female adolescents remain limited. This is not a reason to withhold treatment from adolescents with established fragility fractures, but it does mean prescribers should reassess annually whether continued therapy is warranted.

Safety Profile in Adolescents

The adverse-event profile of ZA in adolescents parallels that in adults in most respects, with a few age-specific considerations.

Acute-Phase Reaction

The most common adverse event after the first infusion is an acute-phase reaction: fever (temperature above 38°C), myalgia, arthralgia, and fatigue, typically appearing within 24 to 48 hours and resolving within 3 days. This occurs in approximately 30 to 40% of first-time recipients. Pre-medicating with acetaminophen 15 mg/kg (max 1,000 mg) before infusion and every 6 hours for 24 hours reduces severity. Reactions are substantially less common after subsequent infusions. PubMed PMID 21471390

Hypocalcemia

Asymptomatic transient hypocalcemia occurs in up to 20% of pediatric patients receiving ZA. Symptomatic hypocalcemia (tetany, QTc prolongation) is rare when vitamin D is adequate and calcium supplementation is in place. A 2014 analysis of pediatric ZA data found that pre-infusion 25-OH vitamin D below 20 ng/mL was the strongest single predictor of clinically meaningful post-infusion hypocalcemia. PubMed PMID 24384374

Renal Function

Bisphosphonates are cleared renally. In a pooled analysis of pediatric bisphosphonate studies, transient elevations of serum creatinine occurred in 3 to 5% of patients receiving ZA, all resolving within 4 weeks without intervention. Permanent renal impairment has not been reported at weight-based pediatric doses. NCBI PMC4408814

Effects on Growth Plates

Theoretical concern exists that bisphosphonates, which inhibit osteoclast activity, could disrupt the remodeling of metaphyseal bone and affect linear growth. Published pediatric studies, including a 6-year follow-up of 58 children with OI treated with intravenous bisphosphonates, found no significant difference in standing height Z-scores compared with untreated OI controls. PubMed PMID 19386733

Osteonecrosis of the Jaw (ONJ)

ONJ is a recognized complication of bisphosphonate therapy, primarily reported in adults receiving high-dose IV bisphosphonates for oncologic indications. In the pediatric bone fragility literature, ONJ has been reported only in isolated case reports. The absolute risk in adolescents receiving low-dose annual ZA for non-oncologic conditions appears to be extremely low, though dental evaluation and any invasive dental work should be completed before starting therapy. FDA drug safety communication on bisphosphonates and ONJ

Monitoring During Therapy

Ongoing laboratory and clinical surveillance is essential. The following schedule reflects current practice at major pediatric metabolic bone centers:

Before Each Infusion

• Serum creatinine and eGFR
• Serum calcium (total and ionized if available)
• Serum phosphate
• 25-OH vitamin D level
• Complete blood count if on concurrent immunosuppressants

At 6-Month Intervals

• DXA scan of lumbar spine (L1, L4) with Z-score reporting using pediatric reference databases
• Lateral spine radiograph if vertebral fractures are suspected or known
• Anthropometric measurements (height, weight) to track growth trajectory

Annual Reassessment

• Review of fracture history and incident fractures since last visit
• Assessment of whether ongoing therapy is warranted based on fracture risk, BMD trajectory, and proximity to skeletal maturity
• Discussion with the patient and family regarding treatment duration and eventual transition plan

The Endocrine Society recommends that bisphosphonate therapy in children be reassessed at least annually, with consideration of a drug holiday once the patient reaches skeletal maturity and fracture risk has stabilized. Endocrine Society JCE guidelines on bone disease management

Special Populations Within the 12 to 17 Age Group

Adolescents With Severe OI (Types III and IV)

These patients have the strongest evidence base and the most urgent clinical need. Annual ZA at 0.05 mg/kg is appropriate, with dose capped at 4 mg. Some centers use a loading protocol with two infusions 6 months apart in the first treatment year followed by annual maintenance. DXA every 12 months with vertebral imaging every 24 months is recommended. PubMed PMID 19386733

Adolescent Females With Anorexia Nervosa

Low bone mass is extremely common in adolescent females with anorexia nervosa (AN). A study by Miller et al. Found that 38% of adolescent females with AN had lumbar spine BMD Z-scores below minus 2.0. Weight restoration is the primary treatment, but ZA has been studied as an adjunct. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (PMID 21367929) found that a single 1 mg IV dose of ZA increased hip BMD by 1.7% over 12 months in adolescents and young adults with AN compared with 0.1% in the placebo group (P<0.05). Given limited evidence and potential teratogenicity concerns in females who may become pregnant, ZA in AN should be restricted to patients with a history of fragility fracture and BMD Z-score below minus 2.0. PubMed PMID 21367929

Adolescents Approaching Skeletal Maturity

Bone accrual continues until approximately age 25, with peak bone mass largely achieved by age 18 to 20. In late adolescents (ages 16 to 17) nearing skeletal maturity, some clinicians transition from weight-based pediatric dosing toward the adult 5 mg annual dose if body weight exceeds 50 kg and growth has nearly ceased. This transition should be documented with clinical justification and informed consent discussion. NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases on bone health

Informed Consent Considerations

Because ZA is used off-label in this age group, informed consent must explicitly cover:

• Off-label status: The family and the adolescent (using age-appropriate language) must understand the drug is not FDA-approved for their age group.
• Evidence quality: Explain that available data come from small trials and observational studies, not large Phase 3 randomized controlled trials with adolescent subjects.
• Teratogenicity: Bisphosphonates incorporate into bone and are released slowly over years. Animal studies show fetal harm. Female adolescents with any reproductive potential must understand the risk before and during pregnancy. Bone-incorporated ZA could theoretically release during a subsequent pregnancy. This is not a reason to categorically deny treatment in adolescents with high fracture risk, but the discussion must occur and be documented.
• Duration uncertainty: No agreed-upon treatment endpoint has been established for pediatric bisphosphonate therapy.
• Drug holiday planning: Treatment is not indefinite; a reassessment plan should be communicated at the outset.

The American College of Obstetricians and Gynecologists addresses bisphosphonate use in women of reproductive age in its clinical guidance on osteoporosis management, noting that the decision to treat must weigh skeletal risk against reproductive risk. ACOG clinical guidance on osteoporosis in younger women

Prescribing Workflow for Adolescent ZA

The following is a practical outline for clinicians managing adolescent ZA therapy:

1. Confirm indication and document fracture history, DXA Z-score, and underlying diagnosis.
2. Order baseline labs: serum calcium, phosphate, creatinine, 25-OH vitamin D, CBC.
3. Correct vitamin D deficiency to at least 20 ng/mL before infusion.
4. Verify no invasive dental procedures are pending; refer to dentist if needed.
5. Calculate weight-based dose (0.025 to 0.05 mg/kg, max 4 mg); document dose and rationale.
6. Obtain and document informed consent covering off-label status, teratogenicity, and monitoring plan.
7. Prescribe pre-medication: acetaminophen 15 mg/kg (max 1,000 mg) 30 minutes before infusion and every 6 hours for 24 hours post-infusion.
8. Administer IV ZA diluted in 100 mL NS over at least 15 to 30 minutes with adequate IV hydration.
9. Schedule follow-up labs at 7 to 10 days post-infusion (serum calcium, creatinine).
10. Arrange DXA at 12 months and repeat clinical reassessment for continuation decision.